Enovis (ENOV)
(Delayed Data from NYSE)
$43.75 USD
-0.62 (-1.40%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $43.74 -0.01 (-0.02%) 7:58 PM ET
2-Buy of 5 2
A Value D Growth B Momentum B VGM
Price, Consensus and EPS Surprise
ENOV 43.75 -0.62(-1.40%)
Will ENOV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ENOV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENOV
5 Medical Info Systems Stock to Buy for a Stable Portfolio
Compelling Reasons to Hold on to HCA Healthcare (HCA) Stock
ENOV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ensign Group (ENSG) Buys Facilities in Arizona & Colorado
Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst
3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare
Other News for ENOV
Top 3 Health Care Stocks That Could Blast Off In June
August 16th Options Now Available For Enovis (ENOV)
Enovis initiated with neutral view at JPMorgan, here's why
Interesting ENOV Put And Call Options For April 2025
Alan Fournier's Strategic Moves in Q1 2024 Highlighted by Major Stake in Enovis Corp